New Entries to China Drug Market to Garner More Than $270 Million in
Combined Sales, According to a New Report by Decision Resources
WALTHAM, Mass., May 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the Chinese type 2 diabetes drug market will more than triple by 2012. According to the new Emerging Markets report entitled Type 2 Diabetes in China, this growth will be fueled by increased access to health insurance, greater patient spending power and more aggressive treatment practice, leading to increased usage of newer agents such as the insulin analogues. Additionally, the number of prevalent cases of type 2 diabetes in China is among the highest in the world -- 62.5 million cases in 2007 -- a number that rivals that of the United States, Europe and Japan combined (48.5 million cases). The high prevalence rate in China reflects an aging population and urbanization-associated risk factors, such as diet and lack of physical activities.
"The Chinese government and medical associations are promoting guidelines published by the American Diabetes Association, the World Health Organization and the Chinese Society of Diabetes," said Victor Li, Ph.D., analyst at Decision Resources. "All guidelines advocate earlier and more-aggressive interventions in type 2 diabetes patients. We forecast that the patient population treated with polypharmacy will nearly double between 2007 and 2012."
The report also finds that three new type 2 diabetes agents with novel
mechanisms -- Eli Lilly/Amylin's Byetta, Merck's Januvia and Novartis's
Galvus -- are expected to launch in China by 2012. The combined sales of
these three agents will surpass $270 million by 2012. However, the high
cost of many antidiabetic therapies, particularly Western-branded drugs, is
a major barrier to effective management of type 2 diabetes in China.
Patient ability to p
|SOURCE Decision Resources, Inc.|
Copyright©2008 PR Newswire.
All rights reserved